Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

DANAHER CORPORATION

Filed by LEWIS-BURKE ASSOCIATES, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-02 06:26:10 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 14, 2026
Income
$36,000.00
Expenses
Not reported
Filing UUID
bb98967e-35c2-43f6-9be9-7f30c0638313
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues pertaining to the regulation of cell and gene therapy products. Issues pertaining to the biomedical research enterprise.

BUD · Budget/Appropriations

H.R. 8646, FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, Issues related to cell and gene therapy products at FDA.

Literal federal measure citations: H.R. 8646

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.